76 281

Cited 0 times in

Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy

DC Field Value Language
dc.contributor.author금웅섭-
dc.contributor.author노미령-
dc.contributor.author신상준-
dc.contributor.author오병호-
dc.contributor.author이충근-
dc.contributor.author장지석-
dc.contributor.author정기양-
dc.contributor.author정민규-
dc.date.accessioned2021-05-21T16:40:26Z-
dc.date.available2021-05-21T16:40:26Z-
dc.date.issued2020-07-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182522-
dc.description.abstractPurpose: We investigated the clinical efficacy of immune checkpoint blocker (ICB) therapy for metastatic or advanced melanoma in Korean patients. As well, we assessed whether the effects of ICBs can be enhanced by combination therapy with palliative radiotherapy (RT). Materials and methods: We retrospectively reviewed the records of 127 patients with metastatic melanoma who received ICB with or without palliative RT between 2014 and 2018. The melanoma subtypes were classified as follows: chronic sun-damaged (CSD), acral, mucosal, and uveal. The primary endpoint was the objective response rate (ORR). Results: The overall ORR was 15%, with 11 complete and eight partial responses. ORRs for CSD, acral/mucosal, and uveal melanomas were 50%, 16.5%, and 0%, respectively (p=0.009). In addition to the subtype, stage at treatment, total tumor burden at treatment, and ICB type were significantly associated with ORR (all p < 0.05). Palliative RT was administered in 44% of patients during the treatment, and it did not affect ORR. Clinical responders to ICB therapy exhibited significantly higher 1-year progression-free and overall survival rates than nonresponders. Conclusion: ORR for ICB monotherapy in Korean patients with melanoma is relatively modest compared with that in Western patients because the non-CSD subtypes are predominant in the Korean population. Our findings regarding combination therapy with ICB provided a rationale for the initiation of our phase II study (NCT04017897).-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHImmune Checkpoint Inhibitors / therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMelanoma / drug therapy-
dc.subject.MESHMelanoma / mortality*-
dc.subject.MESHMelanoma / pathology-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPatient Selection*-
dc.subject.MESHPrognosis-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHYoung Adult-
dc.titleClinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorJeongshim Lee-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorMi Ryung Roh-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorChoong-Kun Lee-
dc.contributor.googleauthorByung Ho Oh-
dc.contributor.googleauthorKee Yang Chung-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorSang Joon Shin-
dc.identifier.doi10.4143/crt.2019.598-
dc.contributor.localIdA00273-
dc.contributor.localIdA01278-
dc.contributor.localIdA02105-
dc.contributor.localIdA02367-
dc.contributor.localIdA03259-
dc.contributor.localIdA04658-
dc.contributor.localIdA03582-
dc.contributor.localIdA03606-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid32054150-
dc.subject.keywordAsia-
dc.subject.keywordImmune checkpoint blocker-
dc.subject.keywordImmunotherapy-
dc.subject.keywordMelanoma-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.affiliatedAuthor금웅섭-
dc.contributor.affiliatedAuthor노미령-
dc.contributor.affiliatedAuthor신상준-
dc.contributor.affiliatedAuthor오병호-
dc.contributor.affiliatedAuthor이충근-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor정기양-
dc.contributor.affiliatedAuthor정민규-
dc.citation.volume52-
dc.citation.number3-
dc.citation.startPage730-
dc.citation.endPage738-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.52(3) : 730-738, 2020-07-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.